R
Robert S. Brown
Researcher at Cornell University
Publications - 1287
Citations - 73376
Robert S. Brown is an academic researcher from Cornell University. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 130, co-authored 1243 publications receiving 65822 citations. Previous affiliations of Robert S. Brown include Beth Israel Deaconess Medical Center & Harvard University.
Papers
More filters
Journal ArticleDOI
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault,Anna S. Lok,Brian J. McMahon,Kyong-Mi Chang,Jessica P. Hwang,Maureen M. Jonas,Robert S. Brown,Natalie Bzowej,John B. Wong +8 more
TL;DR: This AASLD 2018 Hepatitis B Guidance provides a data-supported approach to screening, prevention, diagnosis, and clinical management of patients with hepatitis B.
Journal ArticleDOI
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch,Ann-Marie Patch,Elizabeth L. Christie,Dariush Etemadmoghadam,Dariush Etemadmoghadam,Dale W. Garsed,Joshy George,Sian Fereday,Katia Nones,Katia Nones,Prue A. Cowin,Kathryn Alsop,Peter Bailey,Peter Bailey,Karin S. Kassahn,Karin S. Kassahn,Felicity Newell,Michael C.J. Quinn,Michael C.J. Quinn,Stephen H. Kazakoff,Stephen H. Kazakoff,Kelly Quek,Charlotte Wilhelm-Benartzi,Edward Curry,Huei San Leong,Anne Hamilton,Anne Hamilton,Anne Hamilton,Linda Mileshkin,George Au-Yeung,Catherine Kennedy,Jillian Hung,Yoke Eng Chiew,Paul R. Harnett,Michael Friedlander,Michael C. J. Quinn,Jan Pyman,Stephen Cordner,Patricia C. M. O’Brien,Jodie Leditschke,Greg Young,Kate Strachan,Paul Waring,Walid J Azar,Chris Mitchell,Nadia Traficante,Joy Hendley,Heather Thorne,Mark Shackleton,David Miller,Gisela Mir Arnau,Richard W. Tothill,Timothy P. Holloway,Timothy Semple,Ivon Harliwong,Craig Nourse,Ehsan Nourbakhsh,Suzanne Manning,Senel Idrisoglu,Timothy J. C. Bruxner,Angelika N. Christ,Barsha Poudel,Oliver Holmes,Oliver Holmes,Matthew J. Anderson,Conrad Leonard,Conrad Leonard,Andrew Lonie,Nathan E. Hall,Scott Wood,Scott Wood,Darrin Taylor,Qinying Xu,Qinying Xu,J. Lynn Fink,Nick Waddell,Ronny Drapkin,Euan A. Stronach,Hani Gabra,Robert S. Brown,A. Jewell,Shivashankar H. Nagaraj,Emma Markham,Peter Wilson,Jason Ellul,Orla McNally,Maria A. Doyle,Ravikiran Vedururu,Collin Stewart,Ernst Lengyel,John V. Pearson,John V. Pearson,Nicola Waddell,Nicola Waddell,Anna deFazio,Sean M. Grimmond,Sean M. Grimmond,David D.L. Bowtell,David D.L. Bowtell,David D.L. Bowtell +99 more
TL;DR: It is shown that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance.
Journal ArticleDOI
A constitutive equation for concentrated suspensions that accounts for shear‐induced particle migration
TL;DR: In this article, a constitutive equation for computing particle concentration and velocity fields in concentrated monomodal suspensions is proposed that consists of two parts: a Newtonian constitutive equations in which the viscosity depends on the local particle volume fraction and a diffusion equation that accounts for shear-induced particle migration.
Journal ArticleDOI
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation
TL;DR: The purpose of the current Guidelines is to provide an evidence-based set of recommendations for the evaluation of adult patients who are potentially candidates for LT, and they are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case.
Journal ArticleDOI
Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
Michael P. Curry,Jacqueline G. O'Leary,Natalie Bzowej,Andrew J. Muir,Kevin M. Korenblat,Jonathan M. Fenkel,K. R. Reddy,E. Lawitz,Steven L. Flamm,T. Schiano,L. Teperman,Robert J. Fontana,E. Schiff,Michael W. Fried,Brian P. Doehle,D. An,J. McNally,A. O. Osinusi,Diana M. Brainard,John G. McHutchison,Robert S. Brown,Michael Charlton +21 more
TL;DR: Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with so-called "superdrugs" for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis.